Clinical Trial Update: A Study Comparing Pemetrexed Plus Cisplatin Versus Pemetrexed Alone in NSCLC Patients Who Have Progressed on First Line EGFR-TKI [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial comparing pemetrexed plus cisplatin versus pemetrexed alone in non-small cell lung cancer patients who progressed after first-line EGFR…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Alimta (pemetrexed)
• Platinol (cisplatin)

Snippet

Sponsor: Samsung Medical Center | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: UNKNOWN